| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Victoria Higgins, Khosrow Adel. Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment. EJIFCC. vol 28. issue 3. 2020-09-30. PMID:29075168. |
glucagon-like-peptide 1; glp-1) have been shown to regulate chylomicron output, alterations in these signaling pathways in insulin resistant states may play a role in the development and/or progression of postprandial dyslipidemia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Wesley Nuffer, Ashley Guesnier, Jennifer M Trujill. A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products. Therapeutic advances in endocrinology and metabolism. vol 9. issue 3. 2020-09-30. PMID:29492243. |
a review of the new glp-1 receptor agonist/basal insulin fixed-ratio combination products. |
2020-09-30 |
2023-08-13 |
Not clear |
| Wesley Nuffer, Ashley Guesnier, Jennifer M Trujill. A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products. Therapeutic advances in endocrinology and metabolism. vol 9. issue 3. 2020-09-30. PMID:29492243. |
there have been several new treatment approaches established for the management of hyperglycemia in type 2 diabetes (t2d), with treatment guidelines listing both glucagon-like peptide 1 receptor agonists (glp-1 ras) and basal insulin therapies as considerations for patients who have failed to control their blood glucose with oral antidiabetic agents. |
2020-09-30 |
2023-08-13 |
Not clear |
| Wesley Nuffer, Ashley Guesnier, Jennifer M Trujill. A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products. Therapeutic advances in endocrinology and metabolism. vol 9. issue 3. 2020-09-30. PMID:29492243. |
until recently, both glp-1 ras and basal insulin therapies were only available as single agents, but there are now two combination pen devices that deliver both a glp-1 ra and basal insulin simultaneously. |
2020-09-30 |
2023-08-13 |
Not clear |
| Wesley Nuffer, Ashley Guesnier, Jennifer M Trujill. A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products. Therapeutic advances in endocrinology and metabolism. vol 9. issue 3. 2020-09-30. PMID:29492243. |
this article reviews the current clinical evidence evaluating the use of these combination glp-1 ra/basal insulin preparations to treat t2d, presents both potential benefits as well as possible downsides with the use of these agents, and discusses the current place in therapy these products represent in the management of t2d. |
2020-09-30 |
2023-08-13 |
Not clear |
| Taedong Han, Byoung Moon Lee, Yoo Hoi Park, Dong Hoon Lee, Hyun Ho Choi, Taehoon Lee, Hakwon Ki. YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus. Biomolecules & therapeutics. vol 26. issue 2. 2020-09-30. PMID:29495245. |
g protein-coupled receptor 119 (gpr119) is expressed in the pancreas and gastrointestinal tract, and its activation promotes insulin secretion in the beta cells of the pancreatic islets as well as the secretion of glucagon-like peptide-1 (glp-1) in intestinal l cells, consequently improving glucose-stimulated insulin secretion. |
2020-09-30 |
2023-08-13 |
mouse |
| Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah, Hrvoje Vrazi. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 3. 2020-09-30. PMID:29713961. |
a systematic literature review and network meta-analysis comparing once-weekly semaglutide with other glp-1 receptor agonists in patients with type 2 diabetes previously receiving basal insulin. |
2020-09-30 |
2023-08-13 |
Not clear |
| Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah, Hrvoje Vrazi. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 3. 2020-09-30. PMID:29713961. |
currently, no head-to-head trial investigating once-weekly semaglutide as an add-on to basal insulin vs other glp-1 receptor agonists (glp-1 ras) is available. |
2020-09-30 |
2023-08-13 |
Not clear |
| Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah, Hrvoje Vrazi. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 3. 2020-09-30. PMID:29713961. |
the aim of this study was to conduct a network meta-analysis (nma) to assess the efficacy and safety of once-weekly semaglutide vs other glp-1 ras in patients with t2d inadequately controlled on basal insulin. |
2020-09-30 |
2023-08-13 |
Not clear |
| Taylor R Inman, Erika Plyushko, Nicholas P Austin, Jeremy L Johnso. The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes. Therapeutic advances in endocrinology and metabolism. vol 9. issue 5. 2020-09-30. PMID:29796245. |
the role of basal insulin and glp-1 receptor agonist combination products in the management of type 2 diabetes. |
2020-09-30 |
2023-08-13 |
Not clear |
| Taylor R Inman, Erika Plyushko, Nicholas P Austin, Jeremy L Johnso. The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes. Therapeutic advances in endocrinology and metabolism. vol 9. issue 5. 2020-09-30. PMID:29796245. |
basal insulin has been a standard treatment option for years, while glucagon-like peptide-1 receptor agonists (glp-1 ras) have grown in use over the past decade due to glucose-lowering efficacy and weight loss potential. |
2020-09-30 |
2023-08-13 |
Not clear |
| Taylor R Inman, Erika Plyushko, Nicholas P Austin, Jeremy L Johnso. The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes. Therapeutic advances in endocrinology and metabolism. vol 9. issue 5. 2020-09-30. PMID:29796245. |
united states guidelines recently emphasize the option to use combination injectable therapy with glp-1 ras and basal insulin once the basal insulin has been optimally titrated as a second- or third-line agent in addition to metformin without reaching the goal a1c. |
2020-09-30 |
2023-08-13 |
Not clear |
| Taylor R Inman, Erika Plyushko, Nicholas P Austin, Jeremy L Johnso. The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes. Therapeutic advances in endocrinology and metabolism. vol 9. issue 5. 2020-09-30. PMID:29796245. |
the dual use of basal insulin plus glp-1 ra is non-inferior compared with basal insulin plus a single injection of prandial insulin at the largest meal and compared with twice daily-dosed premixed insulins; and this combination is associated with weight loss and less hypoglycemia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Danielle T Vannan, Marc R Bomhof, Raylene A Reime. Comparison of Glucose and Satiety Hormone Response to Oral Glucose vs. Two Mixed-Nutrient Meals in Rats. Frontiers in nutrition. vol 5. 2020-09-30. PMID:30320120. |
blood was collected via tail snip and analyzed for glucose, insulin, glp-1, gip, pyy, amylin, leptin, and ghrelin. |
2020-09-30 |
2023-08-13 |
rat |
| Matteo Tacelli, Ciro Celsa, Bianca Magro, Aurora Giannetti, Grazia Pennisi, Federica Spatola, Salvatore Pett. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? Pharmaceuticals (Basel, Switzerland). vol 11. issue 4. 2020-09-30. PMID:30413050. |
glp-1 analogues stimulate insulin secretion by pancreatic beta cell and inhibit glucagon release; liraglutide is the most used drug in this class and significantly improves steatosis, hepatocyte ballooning and transaminase levels. |
2020-09-30 |
2023-08-13 |
Not clear |
| Hui Huang, Sanath K Meegalla, James C Lanter, Michael P Winters, Shuyuan Zhao, James Littrell, Jenson Qi, Brian Rady, Paul S Lee, Jianying Liu, Tonya Martin, Wing W Lam, Fran Xu, Heng Keang Lim, Thomas Wilde, Jose Silva, Monicah Otieno, Alessandro Pocai, Mark R Playe. Discovery of a GPR40 Superagonist: The Impact of Aryl Propionic Acid α-Fluorination. ACS medicinal chemistry letters. vol 10. issue 1. 2020-09-30. PMID:30655940. |
gpr40 full agonists exhibit superior glucose lowering compared to partial agonists in preclinical species due to increased insulin and glp-1 secretion, with the added benefit of promoting weight loss. |
2020-09-30 |
2023-08-13 |
Not clear |
| Hyeonhui Kim, Sungsoon Fan. Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis. Laboratory animal research. vol 34. issue 4. 2020-09-30. PMID:30671099. |
interestingly, bile acids have shown to activate tgr5 in intestinal l cells and enhance secretion of glucagon-like peptide 1 (glp-1) to potentiate insulin secretion in response to glucose. |
2020-09-30 |
2023-08-13 |
Not clear |
| Andrea N Suarez, Emily E Noble, Scott E Kanosk. Regulation of Memory Function by Feeding-Relevant Biological Systems: Following the Breadcrumbs to the Hippocampus. Frontiers in molecular neuroscience. vol 12. 2020-09-30. PMID:31057368. |
we review evidence that gut-to-brain communication from the vagus nerve and from feeding-relevant endocrine systems, including ghrelin, insulin, leptin, and glucagon-like peptide-1 (glp-1), promote hippocampal-dependent spatial and declarative memory |
2020-09-30 |
2023-08-13 |
Not clear |
| Alyce M Martin, Emily W Sun, Geraint B Rogers, Damien J Keatin. The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release. Frontiers in physiology. vol 10. 2020-09-30. PMID:31057420. |
enteroendocrine cells within the mucosal lining of the gut synthesize and secrete a number of hormones including cck, pyy, glp-1, gip, and 5-ht, which have regulatory roles in key metabolic processes such as insulin sensitivity, glucose tolerance, fat storage, and appetite. |
2020-09-30 |
2023-08-13 |
human |
| Christian Hölsche. Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease. Frontiers in aging neuroscience. vol 11. 2020-09-30. PMID:31068799. |
treatments to re-sensitize insulin signaling in the brain are also described, such as nasal insulin tests in ad patients, or treatments with re-sensitizing hormones, such as leptin, ghrelin, glucagon-like peptide 1 (glp-1),and glucose-dependent insulinotropic polypeptide (gip). |
2020-09-30 |
2023-08-13 |
Not clear |